Construction and validation of a prognostic signature based on seven endoplasmic reticulum stress-related lncRNAs for patients with head and neck squamous cell carcinoma

被引:4
作者
Zhou, Mingzhu [1 ]
Li, Huihui [2 ]
Hu, Juanjuan [1 ]
Zhou, Tao [1 ]
Zhou, Liuqing [1 ]
Li, Yuncheng [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Phys Examinat Ctr, Wuhan, Peoples R China
关键词
CANCER; RNA;
D O I
10.1038/s41598-023-49987-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Endoplasmic reticulum stress (ERS) occurs when misfolded or unfolded proteins accumulate in the endoplasmic reticulum (ER), and it is often observed in tumors, including head and neck squamous cell carcinoma (HNSCC). Relevant studies have demonstrated the prognostic significance of ERS-related long non-coding RNAs (lncRNAs) in various cancers. However, the relationship between ERS and lncRNAs in HNSCC has received limited attention in previous studies. In this study, we aimed to develop an ERS-related lncRNAs prognostic model using correlation analysis, Cox regression analysis, least absolute shrinkage, and selection operator (LASSO) regression analysis based on data from The Cancer Genome Atlas (TCGA) database. The survival and predictive ability of this model were evaluated using Kaplan-Meier analysis and time-dependent receiver operating characteristics (ROC), while nomograms and calibration curves were constructed. Then, functional enrichment analyses, tumor mutation burden (TMB), tumor infiltration of immune cells, single sample Gene Set Enrichment Analysis (ssGSEA), and drug sensitivity analysis were performed. Additionally, we conducted a consensus cluster analysis to compare differences between subtypes of tumors. Finally, we validated the expression of the ERS-related lncRNAs that constructed prognostic risk score model in HNSCC tissues through quantitative real-time PCR (qRT-PCR). We developed a prognostic signature based on seven ERS-related lncRNAs, which showed better predictive performance than other clinicopathological features. The high-risk poor prognosis group had a poorer prognosis in comparison to the low-risk good prognosis. The area under the ROC curve (AUC) predicted by this model for 3-year survival rates of HNSCC patients was 0.805. Enrichment analysis revealed that the differentially expressed genes were primarily enriched in pathways related to immune responses and signal transduction. Low-risk patients had lower TMB, more immune cell infiltrations, and enhanced anti-tumor immunity. Cluster analysis indicated that cluster 3 may have a better prognosis and immunotherapy effect. In addition, the result of qRT-PCR was consistent with our analysis. This prognostic model based on seven ERS-related lncRNAs is a promising tool for risk stratification, survival prediction, and immune cell infiltration status assessment.
引用
收藏
页数:18
相关论文
共 51 条
  • [1] Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications
    Almanza, Aitor
    Carlesso, Antonio
    Chintha, Chetan
    Creedican, Stuart
    Doultsinos, Dimitrios
    Leuzzi, Brian
    Luis, Andreia
    McCarthy, Nicole
    Montibeller, Luigi
    More, Sanket
    Papaioannou, Alexandra
    Pueschel, Franziska
    Sassano, Maria Livia
    Skoko, Josip
    Agostinis, Patrizia
    de Belleroche, Jackie
    Eriksson, Leif A.
    Fulda, Simone
    Gorman, Adrienne M.
    Healy, Sandra
    Kozlov, Andrey
    Munoz-Pinedo, Cristina
    Rehm, Markus
    Chevet, Eric
    Samali, Afshin
    [J]. FEBS JOURNAL, 2019, 286 (02) : 241 - 278
  • [2] The status of tumor mutational burden and immunotherapy
    Anagnostou, Valsamo
    Bardelli, Alberto
    Chan, Timothy A.
    Turajlic, Samra
    [J]. NATURE CANCER, 2022, 3 (06) : 652 - 656
  • [3] xCell: digitally portraying the tissue cellular heterogeneity landscape
    Aran, Dvir
    Hu, Zicheng
    Butte, Atul J.
    [J]. GENOME BIOLOGY, 2017, 18
  • [4] Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
    Avril, T.
    Vauleron, E.
    Chevet, E.
    [J]. ONCOGENESIS, 2017, 6 : e373 - e373
  • [5] Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
    Becht, Etienne
    Giraldo, Nicolas A.
    Lacroix, Laetitia
    Buttard, Benedicte
    Elarouci, Nabila
    Petitprez, Florent
    Selves, Janick
    Laurent-Puig, Pierre
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    de Reynies, Aurelien
    [J]. GENOME BIOLOGY, 2016, 17
  • [6] Long Noncoding RNA and Cancer: A New Paradigm
    Bhan, Arunoday
    Soleimani, Milad
    Mandal, Subhrangsu S.
    [J]. CANCER RESEARCH, 2017, 77 (15) : 3965 - 3981
  • [7] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, Barbara
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto, Jr.
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Hong, Ruey-Long
    Mendoza, Rene Gonzalez
    Roy, Ananya
    Zhang, Yayan
    Gumuscu, Burak
    Cheng, Jonathan D.
    Jin, Fan
    Rischin, Danny
    [J]. LANCET, 2019, 394 (10212) : 1915 - 1928
  • [8] Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer
    Cai, Jiehui
    Ji, Zeqi
    Wu, Jinyao
    Chen, Lingzhi
    Zheng, Daitian
    Chen, Yaokun
    Zhang, Xinkang
    Xie, Wanchun
    Huang, Jieying
    Chen, Manqi
    Lin, Ru
    Lin, Weixun
    Chen, Yexi
    Li, Zhiyang
    [J]. FRONTIERS IN GENETICS, 2022, 13
  • [9] High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
    Cao, Dedong
    Xu, Huilin
    Xu, Ximing
    Guo, Tao
    Ge, Wei
    [J]. ONCOIMMUNOLOGY, 2019, 8 (09):
  • [10] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56